Abbott's Receives FDA Approval For Esprit BTK Everolimus Eluting Resorbable Scaffold System

Abbott Laboratories +1.91%

Abbott Laboratories




  • More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options
  • The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK)
  • The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD


Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via